UnitedHealth has traditionally been a company investors saw as reliable, having not missed earnings estimates since the 2008 global financial crisis.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

Analysts at Leerink agreed with Sanofi that, despite falling short of statistical significance in the Phase II TIDE-Asthma trial, amlitelimab warrants further development in this indication.

Pamalican Asset Management just snagged 6,900 shares of Regeneron Pharmaceuticals, making the biotech giant its 16th largest ...

Research analysts at Leerink Partnrs dropped their FY2026 earnings per share estimates for Alnylam Pharmaceuticals in a report issued on Wednesday, April 2nd. Leerink Partnrs analyst M. Foroohar now ...

Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a research report issued on Tuesday, April 1st. Leerink Partnrs analyst D.

Biotech stocks toppled early Thursday after Trump announced broad global tariffs, including a 20% tariff on goods from Europe.

Fintel reports that on March 28, 2025, Leerink Partners downgraded their outlook for Equillium (LSE:0A4D) from Outperform to Market Perform. There are 35 funds or institutions reporting positions ...

At the low end of effective tax rates is Regeneron Pharmaceuticals (NASDAQ: REGN), which has issued effective tax rate guidance for 2025 of 9% to 11%. With manufacturing split between Rensselaer ...

Since then, RGNX has gained (% wise) what SRPT has lost. Leerink notes that shares of Outperform-rated Sarepta are under pressure on the heels of the disclosure of a patient death following ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other best extremely profitable stocks to buy according to analysts. We recently ...